INNV - Innovus Pharmaceuticals, Inc. Stock Price, Fair Value and News

3.84USD+0.04 (+1.05%)Market Closed

Market Summary

USD3.84+0.04

Market Closed

1.05%

INNV Stock Price

View Fullscreen

INNV RSI Chart

INNV Valuation

Market Cap

521.9M

Price/Earnings (Trailing)

-16.54

Price/Sales (Trailing)

0.72

Price/Free Cashflow

-40.35

INNV Price/Sales (Trailing)

INNV Profitability

Return on Equity

-11.05%

Return on Assets

-5.91%

Free Cashflow Yield

-2.48%

INNV Fundamentals

INNV Revenue

Revenue (TTM)

720.8M

Rev. Growth (Yr)

12.8%

Rev. Growth (Qtr)

3.51%

INNV Earnings

Earnings (TTM)

-31.6M

Earnings Growth (Yr)

64.8%

Earnings Growth (Qtr)

66.55%

Breaking Down INNV Revenue

Last 7 days

-2.8%

Last 30 days

-11.5%

Last 90 days

-34.5%

Trailing 12 Months

-35.5%

How does INNV drawdown profile look like?

INNV Financial Health

Current Ratio

1.27

Debt/Equity

0.22

Debt/Cashflow

8e-4

INNV Investor Care

Shares Dilution (1Y)

0.22%

Diluted EPS (TTM)

-0.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	684.1M	688.1M	699.4M	720.8M
2022	697.4M	698.6M	696.8M	688.9M
2021	620.1M	637.8M	658.3M	676.3M
2020	0	567.2M	584.8M	602.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Innovus Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	bent christine	sold (taxes)	-34,936	4.00	-8,734	chief operations officer
Mar 01, 2024	blair patrick t	sold (taxes)	-17,366	4.87	-3,566	president and ceo
Feb 22, 2024	ignite aggregator lp	sold	-	-	-3,532,540	-
Feb 22, 2024	tco group holdings, l.p.	sold	-	-	-3,532,540	-
Feb 22, 2024	welsh, carson, anderson & stowe xii, l.p.	sold	-	-	-3,532,540	-
Dec 01, 2023	blair patrick t	sold (taxes)	-19,599	5.9	-3,322	president and ceo
Sep 01, 2023	blair patrick t	sold (taxes)	-26,418	5.57	-4,743	president and ceo
Aug 30, 2023	blair patrick t	acquired	-	-	105,264	president and ceo
Aug 15, 2023	feifer richard	sold (taxes)	-54,527	5.6	-9,737	chief medical officer
Aug 15, 2023	damato nicole	sold (taxes)	-54,168	5.6	-9,673	chief legal officer

Which funds bought or sold INNV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-4.67	-85,033	203,681	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.38	-13,000	3,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-65,129	-	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	sold off	-100	-	-	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-4.08	-447,630	10,977,400	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	83.59	100,502	220,296	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	-134	56,424	-%
Feb 15, 2024	Legal & General Group Plc	unchanged	-	-18.00	11,033	-%
Feb 15, 2024	BARCLAYS PLC	added	690	136,000	155,000	-%

Are Funds Buying or Selling INNV?

Are funds buying INNV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INNV

No. of Funds

Unveiling Innovus Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 11, 2022	tco group holdings, l.p.	85.98%	116,520,612	SC 13G

Recent SEC filings of Innovus Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Feb 27, 2024	8-K	Current Report
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 06, 2024	8-K	Current Report
Feb 06, 2024	10-Q	Quarterly Report

Peers (Alternatives to Innovus Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	456.6B	371.6B	0.44%	0.97%	20.4	1.23	14.64%	11.24%
CI	103.6B	195.3B	-2.45%	41.59%	19.29	0.53	8.17%	-20.79%
CVS	84.5B	357.8B	-15.42%	-8.05%	10.12	0.24	10.95%	93.52%
HCA	81.1B	65.0B	-7.58%	8.53%	15.47	1.25	7.86%	-7.11%
CNC	39.7B	155.5B	-5.58%	8.00%	14.51	0.26	6.34%	84.42%
DVA	11.7B	12.1B	-2.44%	51.70%	16.93	0.96	4.57%	23.40%
UHS	11.5B	14.3B	-8.81%	13.72%	16.01	0.8	6.59%	6.24%
MID-CAP
CHE	8.5B	2.3B	-13.21%	2.71%	31.02	3.73	6.06%	9.17%
ACHC	6.8B	2.9B	-6.00%	1.13%	-313.66	2.32	12.20%	-107.93%
AMN	2.2B	3.8B	-7.09%	-33.84%	10.27	0.57	-27.73%	-52.50%
AMEH	2.0B	1.4B	-10.80%	1.66%	33.48	1.47	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-8.94%	-17.15%	24.52	1.45	11.31%	35.83%
BKD	1.3B	3.0B	5.61%	63.76%	-6.97	0.44	6.74%	20.73%
BEAT	52.7M	-	-9.91%	-0.99%	-3.6	-	-	-12.94%
AMS	20.1M	21.3M	17.84%	15.27%	37.65	0.94	8.00%	-62.25%

Innovus Pharmaceuticals, Inc. News

Latest updates

Innovus Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	3.5%	188,898	182,485	176,874	172,539	167,456	171,218	172,861	177,359	175,350	173,070	171,616	156,308	157,311	152,566	148,668	144,770
Costs and Expenses	-1.3%	190,683	193,203	187,817	180,708	181,136	187,821	185,207	184,032	172,397	161,410	160,949	161,674	136,769	190,745	-	131,796
S&GA Expenses	8.9%	5,859	5,379	6,126	5,314	3,774	4,413	5,085	6,144	6,679	6,293	7,901	5,592	4,631	4,112	-	4,628
Interest Expenses	41.5%	935	661	2,766	405	223	603	-456	709	674	547	-274	4,876	6,555	5,631	-	2,361
Income Taxes	-50.0%	100	200	518	-1,400	-2,900	-3,470	625	-4,100	1,200	2,996	4,610	-4,264	4,486	4,900	-	2,867
Net Income	66.5%	-3,447	-10,304	-11,177	-6,630	-9,793	-13,073	-12,709	-2,821	1,323	7,686	6,474	-10,510	9,705	-49,654	-	8,138
Net Income Margin	19.2%	-0.04*	-0.05*	-0.06*	-0.06*	-0.06*	-0.04*	-0.01*	0.02*	0.01*	0.02*	-0.07*	0.04*	0.04*	-	-	-
Free Cashflow	69.4%	-10,880	-35,556	9,126	24,378	-42,083	5,461	-14,854	-15,978	2,379	17,517	6,022	-18,904	10,480	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q2
Assets	-2.1%	534	546	567	569	546	585	556	558	558	543	532	531	410
Current Assets	-20.0%	157	196	215	216	199	243	241	250	266	261	251	252	167
Cash Equivalents	-38.8%	54.00	88.00	127	122	99.00	188	184	200	219	218	204	204	115
Net PPE	-	-	-	-	-	186	181	176	164	152	142	143	142	102
Goodwill	14.0%	142	124	124	124	124	124	124	124	124	124	124	124	116
Liabilities	-3.8%	231	241	253	244	214	244	202	192	190	176	174	180	302
Current Liabilities	-11.3%	123	139	148	138	106	131	105	94.00	89.00	81.00	79.00	94.00	77.00
Long Term Debt	-1.3%	63.00	64.00	65.00	66.00	67.00	67.00	68.00	69.00	70.00	71.00	72.00	72.00	210
LT Debt, Current	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	2.00
LT Debt, Non Current	-1.3%	63.00	64.00	65.00	66.00	67.00	67.00	68.00	69.00	70.00	71.00	72.00	72.00	210
Shareholder's Equity	-2.5%	286	293	296	306	318	327	338	350	350	350	341	334	108
Retained Earnings	-7.5%	-49.69	-46.25	-35.94	-24.77	-18.14	-8.34	5.00	17.00	18.00	19.00	11.00	5.00	65.00
Additional Paid-In Capital	0.5%	335	333	332	331	330	329	327	326	326	325	324	323	36.00
Shares Outstanding	0.1%	136	136	136	136	136	136	136	136	136	136	124	121	-
Minority Interest	-1.2%	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	23.00	7.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	71.8%	-9,294	-32,985	13,151	29,075	-35,117	13,127	3,243	-7,518	11,018	20,559	9,480	-16,285	17,315	-18,058	-	-
Share Based Compensation	-3.1%	1,766	1,823	1,152	1,178	1,069	1,209	1,153	845	783	958	562	530	526	46.00	-	-
Cashflow From Investing	-635.8%	-23,111	-3,141	-5,192	-4,697	-51,966	-7,666	-16,660	-9,897	-8,639	-5,042	-3,458	-2,619	-8,835	-4,629	-	-
Cashflow From Financing	29.9%	-1,912	-2,726	-2,416	-2,133	-1,679	-1,668	-1,648	-1,622	-1,596	-1,452	-6,085	143,674	18,636	-40,001	-	-
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	42.00	1.00	-	9,457	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	77,603	-	-

INNV Income Statement

2023-12-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total revenues	$ 188,898	$ 167,456	$ 371,382	$ 338,674
Expenses
External provider costs	100,964	93,507	200,322	189,744
Cost of care, excluding depreciation and amortization	54,321	51,376	109,570	104,933
Sales and marketing	5,859	3,774	11,237	8,187
Corporate, general and administrative	25,249	28,817	54,197	58,999
Depreciation and amortization	4,290	3,662	8,559	7,095
Total expenses	190,683	181,136	383,885	368,958
Operating Loss	(1,785)	(13,680)	(12,503)	(30,284)
Other Income (Expense)
Interest expense, net	(935)	(223)	(1,596)	(826)
Other income	874	444	1,517	480
Other Expenses	(1,882)	0	(1,882)	0
Total other expense	(1,943)	221	(1,961)	(346)
Income (Loss) Before Income Taxes	(3,728)	(13,459)	(14,464)	(30,630)
Provision (Benefit) for Income Taxes	93	(2,912)	319	(6,383)
Net Loss	(3,821)	(10,547)	(14,783)	(24,247)
Less: net loss attributable to noncontrolling interests	(374)	(754)	(1,032)	(1,381)
Net Loss Attributable to InnovAge Holding Corp.	$ (3,447)	$ (9,793)	$ (13,751)	$ (22,866)
Weighted-average number of common shares outstanding - basic (in shares)	135,887,613	135,578,888	135,839,007	135,572,503
Weighted-average number of common shares outstanding - diluted (in shares)	135,887,613	135,578,888	135,839,007	135,572,503
Net loss per share - basic (in dollars per share)	$ (0.03)	$ (0.07)	$ (0.10)	$ (0.17)
Net loss per share - diluted (in dollars per share)	$ (0.03)	$ (0.07)	$ (0.10)	$ (0.17)
Capitation revenue
Revenues
Total revenues	$ 188,561	$ 167,140	$ 370,734	$ 338,071
Other service revenue
Revenues
Total revenues	$ 337	$ 316	$ 648	$ 603

INNV Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Jun. 30, 2023
Current Assets
Cash and cash equivalents	$ 54,081	$ 127,249
Short-term investments	44,690	46,213
Restricted cash	15	16
Accounts receivable, net of allowance ($5,134 – December 31, 2023 and $4,161 – June 30, 2023)	43,456	24,344
Prepaid expenses	14,460	17,145
Income tax receivable	262	262
Total current assets	156,964	215,229
Noncurrent Assets
Property and equipment, net	195,623	192,188
Operating lease assets	26,477	21,210
Investments	3,611	5,493
Deposits and other	5,154	3,823
Goodwill	141,565	124,217
Other intangible assets, net	4,868	5,198
Total noncurrent assets	377,298	352,129
Total assets	534,262	567,358
Current Liabilities
Accounts payable and accrued expenses	52,372	54,935
Reported and estimated claims	47,247	42,999
Due to Medicaid and Medicare	10,264	9,142
Income tax payable	1,212	1,212
Current portion of long-term debt	3,795	3,795
Current portion of finance lease obligations	4,526	4,722
Current portion of operating lease obligations	3,716	3,530
Deferred revenue	0	28,115
Total current liabilities	123,132	148,450
Noncurrent Liabilities
Deferred tax liability, net	6,555	6,236
Finance lease obligations	11,311	13,114
Operating lease obligations	25,943	18,828
Other noncurrent liabilities	1,187	1,086
Long-term debt, net of debt issuance costs	63,162	64,844
Total liabilities	231,290	252,558
Commitments and Contingencies (See Note 9)
Redeemable Noncontrolling Interests (See Note 4)	11,831	12,708
Stockholders’ Equity
Common stock, $0.001 par value; 500,000,000 authorized as of December 31, 2023 and June 30, 2023; 135,893,070 and 135,639,845 issued shares as of December 31, 2023 and June 30, 2023, respectively	136	136
Additional paid-in capital	335,062	332,107
Retained deficit	(49,695)	(35,944)
Total InnovAge Holding Corp.	285,503	296,299
Noncontrolling interests	5,638	5,793
Total stockholders’ equity	291,141	302,092
Total liabilities and stockholders’ equity	$ 534,262	$ 567,358

About Innovus Pharmaceuticals, Inc.

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.

CEO	Mr. Patrick Blair
WEBSITE	innovage.com
INDUSTRY	Healthcare Plans

Innovus Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Innovus Pharmaceuticals, Inc.? What does INNV stand for in stocks?

INNV is the stock ticker symbol of Innovus Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Innovus Pharmaceuticals, Inc. (INNV)?

As of Fri Apr 26 2024, market cap of Innovus Pharmaceuticals, Inc. is 521.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INNV stock?

You can check INNV's fair value in chart for subscribers.

What is the fair value of INNV stock?

You can check INNV's fair value in chart for subscribers. The fair value of Innovus Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Innovus Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INNV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Innovus Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether INNV is over valued or under valued. Whether Innovus Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Innovus Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INNV.

What is Innovus Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, INNV's PE ratio (Price to Earnings) is -16.54 and Price to Sales (PS) ratio is 0.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INNV PE ratio will change depending on the future growth rate expectations of investors.